In a recent study, the median overall survival of FGFR3::TACC3 fusion-positive glioblastomas was reported to be 31.1 months, significantly longer than that of fusion-negative glioblastomas (19.9 months), with the fusion serving as an independent predictor of better outcome [7]. This evidence concerns the gene FGFR3 and glioblastoma.